CRMD Key Statistics, Chart & Performance
The current stock price of CRMD is 7.44 USD. In the past month the price decreased by -39.95%. In the past year, price decreased by -40.1%.
CRMD Technical Analysis
CRMD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CRMD. CRMD has only an average score on both its financial health and profitability.
CRMD Financial Highlights
Over the last trailing twelve months CRMD reported a non-GAAP Earnings per Share(EPS) of 2.06. The EPS increased by 354.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 75.83% | ||
| ROA | 21.64% | ||
| ROE | 43.43% | ||
| Debt/Equity | 0.39 |
CRMD Forecast & Estimates
13 analysts have analysed CRMD and the average price target is 17.19 USD. This implies a price increase of 131.1% is expected in the next year compared to the current price of 7.44.
For the next year, analysts expect an EPS growth of 939.09% and a revenue growth 685.1% for CRMD
CRMD Ownership
CRMD Latest News, Press Relases and Analysis
About CRMD
Company Profile
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 64 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Company Info
CORMEDIX INC
300 Connell Drive, Suite 4200
Berkeley Heights NEW JERSEY 07922 US
CEO: Khoso Baluch
Employees: 64
Phone: 19085179500
CORMEDIX INC / CRMD FAQ
What does CRMD do?
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 64 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
What is the current price of CRMD stock?
The current stock price of CRMD is 7.44 USD. The price increased by 1.5% in the last trading session.
What is the dividend status of CORMEDIX INC?
CRMD does not pay a dividend.
What is the ChartMill rating of CORMEDIX INC stock?
CRMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for CORMEDIX INC?
CORMEDIX INC (CRMD) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the growth outlook for CORMEDIX INC?
The Revenue of CORMEDIX INC (CRMD) is expected to grow by 685.1% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for CRMD stock?
You can find the ownership structure of CORMEDIX INC (CRMD) on the Ownership tab.